[{"id":"101983fb-7628-475a-80b5-d17bf993dca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02988817","created_at":"2021-12-09T22:53:42.151Z","updated_at":"2024-07-02T16:35:41.314Z","phase":"Phase 1/2","brief_title":"Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors","source_id_and_acronym":"NCT02988817","lead_sponsor":"Genmab","biomarkers":" AXL • MUC16","pipe":" | ","alterations":" AXL expression • AXL positive","tags":["AXL • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL expression • AXL positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enapotamab vedotin (HuMax-AXL-ADC)"],"overall_status":"Completed","enrollment":" Enrollment 306","initiation":"Initiation: 11/23/2016","start_date":" 11/23/2016","primary_txt":" Primary completion: 11/12/2021","primary_completion_date":" 11/12/2021","study_txt":" Completion: 11/12/2021","study_completion_date":" 11/12/2021","last_update_posted":"2023-08-01"},{"id":"cde39ba4-f1a3-4ae2-88e4-185a75217b66","acronym":"NCI-2018-02990","url":"https://clinicaltrials.gov/study/NCT03769311","created_at":"2021-01-18T18:38:59.586Z","updated_at":"2024-07-02T16:35:47.258Z","phase":"Phase 2","brief_title":"Cetuximab in Head and Neck Cancer Patients","source_id_and_acronym":"NCT03769311 - NCI-2018-02990","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" AXL","pipe":" | ","alterations":" AXL expression","tags":["AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 03/15/2022","primary_completion_date":" 03/15/2022","study_txt":" Completion: 03/15/2022","study_completion_date":" 03/15/2022","last_update_posted":"2023-05-24"},{"id":"0550fb9c-b9bd-4921-9d69-c2e4ef4dcbf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00697632","created_at":"2021-01-18T02:36:31.892Z","updated_at":"2024-07-02T16:37:02.876Z","phase":"Phase 1","brief_title":"Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies","source_id_and_acronym":"NCT00697632","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MET • AXL","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • AXL expression","tags":["MET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • AXL expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glesatinib (MGCD265)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-12"}]